<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hahn, Bevra H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Guideline Updates</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-10</style></pages><abstract><style  face="normal" font="default" size="100%">Each year at its annual meeting, the American College of Rheumatology (ACR) introduces new or updated evidenced-based clinical practice recommendations that reflect recent clinical trial results and/or incorporate newly approved treatments. This article discusses updated recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs for rheumatoid arthritis, as well as new guidelines for the management of lupus nephritis.</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>